FNP ANCC & AANP Exam
Bank – OB/GYN + Cardiac
2026 Edition
PART I: THE PRIMER
Mastering the 2026 primary care landscape separates technicians from master diagnosticians.
Your ability to synthesize the Cardiovascular-Kidney-Metabolic (CKM) continuum with advanced
reproductive endocrinology will define your clinical legacy and keep high-risk patients alive.
The "Panic Button" Cheat Sheet:
● AHA 2026 HTN Threshold: Target <130/80 mmHg. Initiate pharmacotherapy in Stage 1 if
PREVENT risk ≥7.5%.
● ACOG Chronic HTN (Pregnancy): Initiate antihypertensives at 140/90 mmHg (CHAP
trial standard).
● HRSA/ASCCP 2026 Cervical CA: FDA-approved self-collected vaginal hrHPV is tier-one
for average-risk (30-65). Positive self-swabs mandate in-clinic speculum reflex cytology.
● HFpEF 2026 Standard: SGLT2 inhibitors are frontline regardless of diabetes status.
● NAMS HRT Window: Estrogen is safe for healthy symptomatic women <60 years old and
<10 years from menopause onset.
PART II: THE ELITE TEST BANK
Questions 1–15: Foundational Syntax & Application
Q1: Under the 2025/2026 AHA/ACC Hypertension Guidelines, which variables were
distinctly removed and added to the PREVENT risk calculator compared to the legacy
Pooled Cohort Equations (PCE)? A) Removed: Age; Added: High-Sensitivity CRP B)
Removed: Race; Added: eGFR, HbA1c, and Social Deprivation Index C) Removed: Gender;
Added: BMI and Lp(a) D) Removed: Smoking status; Added: UACR and continuous glucose
monitoring data
● The Answer: B
● Distractor Analysis: Option A is flawed as age remains the strongest predictor of
ASCVD. Option C is incorrect; sex remains a biological variable in the equations. Option
D is incorrect; smoking remains a critical metric.
● The Mentor's Analysis: The legacy PCE was notoriously flawed for overestimating risk
in certain populations and utilizing race as a biological rather than social construct. The
2026 PREVENT calculator is race-free and reclassifies risk by acknowledging the
Cardiovascular-Kidney-Metabolic (CKM) syndrome, integrating renal health (eGFR,
UACR), metabolic health (HbA1c), and the Social Deprivation Index (zip code).
,PREVENT vs. PCE 2013 Pooled Cohort Equations 2026 PREVENT Calculator
(PCE)
Race Variable Included (Black vs. White) Removed (Race-free)
Age Range 40-79 years 30-79 years
Outcomes ASCVD (MI, Stroke) Total CVD (ASCVD + Heart
Failure)
New Variables None eGFR, HbA1c, UACR, SDI (Zip
Code)
Q2: According to the AHA Cardiovascular-Kidney-Metabolic (CKM) Syndrome staging, a
34-year-old female with a BMI of 31 kg/m2, normal blood pressure, and impaired glucose
tolerance is classified as: A) CKM Stage 0 B) CKM Stage 1 C) CKM Stage 2 D) CKM Stage 3
● The Answer: B
● Distractor Analysis: Stage 0 (A) implies no CKM risk factors. Stage 2 (C) requires
established metabolic risk factors like hypertension, hypertriglyceridemia, or CKD. Stage
3 (D) requires subclinical cardiovascular disease.
● The Mentor's Analysis: Stage 1 CKM is defined strictly by excess or dysfunctional
adiposity. Her BMI >30 and prediabetes (dysfunctional adipose tissue leading to insulin
resistance) place her perfectly in Stage 1. This is your critical window for primordial
prevention before she develops structural vascular damage.
Q3: The 2026 HRSA Women’s Preventive Services Guidelines approve self-collected
vaginal hrHPV testing. Which patient is an appropriate candidate for this modality? A) A
24-year-old with a history of ASCUS B) A 45-year-old average-risk, asymptomatic female due
for routine 5-year screening C) A 35-year-old HIV-positive female D) A 50-year-old presenting
with post-coital bleeding
● The Answer: B
● Distractor Analysis: Option A is under 30; primary hrHPV screening begins at 30, and
ages 21-29 require clinician-collected cytology. Option C is immunocompromised and thus
high-risk. Option D is symptomatic and requires a diagnostic pelvic exam, not routine
screening.
● The Mentor's Analysis: Self-collection is a revolutionary access tool, but it is strictly
guarded. It is exclusively for average-risk, asymptomatic individuals aged 30-65
undergoing routine screening. Applying screening tools to symptomatic patients is a fatal
amateur error that delays diagnostic colposcopy and biopsy.
Q4: Based on the CHAP trial and 2026 ACOG guidelines, at what blood pressure
threshold must pharmacotherapy be initiated for a pregnant patient with chronic
hypertension? A) 160/110 mmHg B) 150/100 mmHg C) 140/90 mmHg D) 130/80 mmHg
● The Answer: C
● Distractor Analysis: Option A is the antiquated legacy threshold reserved for acute
hypertensive emergencies. Option B is an arbitrary middle ground. Option D applies to
non-pregnant adults under AHA guidelines but is too aggressive for placental perfusion.
● The Mentor's Analysis: The CHAP trial fundamentally altered obstetric cardiology. We
no longer wait for severe-range pressures (160/110) to intervene. Treating mild chronic
hypertension in pregnancy at 140/90 mmHg significantly reduces preeclampsia with
severe features and medically indicated preterm birth without compromising fetal growth.
Q5: A 68-year-old female with Heart Failure with Preserved Ejection Fraction (HFpEF) and
no history of diabetes is maximally titrated on an ARB and beta-blocker. What is the 2026
ACC/AHA Class 2a recommended addition to her regimen? A) A GLP-1 Receptor Agonist
, (e.g., Semaglutide) B) A Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (e.g., Dapagliflozin)
C) A direct renin inhibitor (e.g., Aliskiren) D) An Angiotensin-Converting Enzyme (ACE) inhibitor
● The Answer: B
● Distractor Analysis: Option A (GLP-1 RA) has metabolic benefits but no proven direct
efficacy in reducing HF hospitalizations in non-diabetic HFpEF patients. Option C is
contraindicated with an ARB. Option D is redundant and dangerous alongside an ARB.
● The Mentor's Analysis: SGLT2 inhibitors are the greatest pharmacological breakthrough
in heart failure of the decade. They promote osmotic diuresis, reduce preload, and alter
myocardial metabolism independently of insulin pathways. They are indicated for HFpEF
and HFrEF regardless of the patient's diabetes status.
Q6: A 52-year-old male with severe statin intolerance (myopathy) requires LDL-C
lowering. You prescribe Bempedoic acid. What is the precise mechanism of action, and
what specific adverse effect must you monitor? A) Inhibits NPC1L1 transporter; monitor for
cholelithiasis B) Inhibits HMG-CoA reductase; monitor for rhabdomyolysis C) Inhibits ATP-citrate
lyase (ACLY); monitor for hyperuricemia and gout D) Binds PCSK9 receptors; monitor for
injection site reactions
● The Answer: C
● Distractor Analysis: Option A describes Ezetimibe. Option B describes Statins. Option D
describes PCSK9 monoclonal antibodies (e.g., Evolocumab).
● The Mentor's Analysis: Bempedoic acid works upstream of HMG-CoA reductase by
inhibiting ATP-citrate lyase. Crucially, it is a prodrug activated only in the liver, not in
skeletal muscle, which completely bypasses statin-associated muscle symptoms (SAMS).
However, it competes with uric acid transporters in the kidney, increasing the risk of
hyperuricemia and gout flares.
Q7: According to the 2026 HRSA Women's Preventive Services Guidelines, what is the
mandate regarding breast cancer screening for average-risk women? A) Initiate biennial
screening at age 50; supplemental imaging requires a specialist co-pay. B) Initiate screening no
earlier than 40 and no later than 50; supplemental imaging for dense breasts must be covered
without cost-sharing. C) Initiate screening at age 35 for all women; annual MRI is required. D)
Discontinue all screening at age 65 regardless of health status.
● The Answer: B
● Distractor Analysis: Option A relies on outdated cost-sharing loopholes. Option C is too
aggressive and ignores risk stratification. Option D incorrectly applies cervical cancer exit
criteria to breast cancer, which continues to at least age 74.
● The Mentor's Analysis: HRSA closed a massive health equity gap in 2026. Plans must
provide first-dollar coverage (no cost-sharing) not just for the initial mammogram between
40-50, but for any required reflex imaging (ultrasound/MRI) and pathology needed to rule
out malignancy in dense breasts. This stops patients from abandoning diagnostic workups
due to surprise billing.
Q8: A 38-year-old female smoker (1 pack/day) with a BP of 145/92 mmHg requests
contraception. According to the U.S. Medical Eligibility Criteria (USMEC), which option is
a Category 4 (unacceptable health risk)? A) Copper IUD B) Levonorgestrel IUD C)
Progestin-only pill (POP) D) Combined Oral Contraceptive (COC) pill
● The Answer: D
● Distractor Analysis: Options A, B, and C do not contain estrogen and lack the profound
pro-thrombotic and vasoactive risks associated with synthetic estrogen metabolism in the
liver.
● The Mentor's Analysis: Synthetic estrogen increases hepatic production of clotting
Bank – OB/GYN + Cardiac
2026 Edition
PART I: THE PRIMER
Mastering the 2026 primary care landscape separates technicians from master diagnosticians.
Your ability to synthesize the Cardiovascular-Kidney-Metabolic (CKM) continuum with advanced
reproductive endocrinology will define your clinical legacy and keep high-risk patients alive.
The "Panic Button" Cheat Sheet:
● AHA 2026 HTN Threshold: Target <130/80 mmHg. Initiate pharmacotherapy in Stage 1 if
PREVENT risk ≥7.5%.
● ACOG Chronic HTN (Pregnancy): Initiate antihypertensives at 140/90 mmHg (CHAP
trial standard).
● HRSA/ASCCP 2026 Cervical CA: FDA-approved self-collected vaginal hrHPV is tier-one
for average-risk (30-65). Positive self-swabs mandate in-clinic speculum reflex cytology.
● HFpEF 2026 Standard: SGLT2 inhibitors are frontline regardless of diabetes status.
● NAMS HRT Window: Estrogen is safe for healthy symptomatic women <60 years old and
<10 years from menopause onset.
PART II: THE ELITE TEST BANK
Questions 1–15: Foundational Syntax & Application
Q1: Under the 2025/2026 AHA/ACC Hypertension Guidelines, which variables were
distinctly removed and added to the PREVENT risk calculator compared to the legacy
Pooled Cohort Equations (PCE)? A) Removed: Age; Added: High-Sensitivity CRP B)
Removed: Race; Added: eGFR, HbA1c, and Social Deprivation Index C) Removed: Gender;
Added: BMI and Lp(a) D) Removed: Smoking status; Added: UACR and continuous glucose
monitoring data
● The Answer: B
● Distractor Analysis: Option A is flawed as age remains the strongest predictor of
ASCVD. Option C is incorrect; sex remains a biological variable in the equations. Option
D is incorrect; smoking remains a critical metric.
● The Mentor's Analysis: The legacy PCE was notoriously flawed for overestimating risk
in certain populations and utilizing race as a biological rather than social construct. The
2026 PREVENT calculator is race-free and reclassifies risk by acknowledging the
Cardiovascular-Kidney-Metabolic (CKM) syndrome, integrating renal health (eGFR,
UACR), metabolic health (HbA1c), and the Social Deprivation Index (zip code).
,PREVENT vs. PCE 2013 Pooled Cohort Equations 2026 PREVENT Calculator
(PCE)
Race Variable Included (Black vs. White) Removed (Race-free)
Age Range 40-79 years 30-79 years
Outcomes ASCVD (MI, Stroke) Total CVD (ASCVD + Heart
Failure)
New Variables None eGFR, HbA1c, UACR, SDI (Zip
Code)
Q2: According to the AHA Cardiovascular-Kidney-Metabolic (CKM) Syndrome staging, a
34-year-old female with a BMI of 31 kg/m2, normal blood pressure, and impaired glucose
tolerance is classified as: A) CKM Stage 0 B) CKM Stage 1 C) CKM Stage 2 D) CKM Stage 3
● The Answer: B
● Distractor Analysis: Stage 0 (A) implies no CKM risk factors. Stage 2 (C) requires
established metabolic risk factors like hypertension, hypertriglyceridemia, or CKD. Stage
3 (D) requires subclinical cardiovascular disease.
● The Mentor's Analysis: Stage 1 CKM is defined strictly by excess or dysfunctional
adiposity. Her BMI >30 and prediabetes (dysfunctional adipose tissue leading to insulin
resistance) place her perfectly in Stage 1. This is your critical window for primordial
prevention before she develops structural vascular damage.
Q3: The 2026 HRSA Women’s Preventive Services Guidelines approve self-collected
vaginal hrHPV testing. Which patient is an appropriate candidate for this modality? A) A
24-year-old with a history of ASCUS B) A 45-year-old average-risk, asymptomatic female due
for routine 5-year screening C) A 35-year-old HIV-positive female D) A 50-year-old presenting
with post-coital bleeding
● The Answer: B
● Distractor Analysis: Option A is under 30; primary hrHPV screening begins at 30, and
ages 21-29 require clinician-collected cytology. Option C is immunocompromised and thus
high-risk. Option D is symptomatic and requires a diagnostic pelvic exam, not routine
screening.
● The Mentor's Analysis: Self-collection is a revolutionary access tool, but it is strictly
guarded. It is exclusively for average-risk, asymptomatic individuals aged 30-65
undergoing routine screening. Applying screening tools to symptomatic patients is a fatal
amateur error that delays diagnostic colposcopy and biopsy.
Q4: Based on the CHAP trial and 2026 ACOG guidelines, at what blood pressure
threshold must pharmacotherapy be initiated for a pregnant patient with chronic
hypertension? A) 160/110 mmHg B) 150/100 mmHg C) 140/90 mmHg D) 130/80 mmHg
● The Answer: C
● Distractor Analysis: Option A is the antiquated legacy threshold reserved for acute
hypertensive emergencies. Option B is an arbitrary middle ground. Option D applies to
non-pregnant adults under AHA guidelines but is too aggressive for placental perfusion.
● The Mentor's Analysis: The CHAP trial fundamentally altered obstetric cardiology. We
no longer wait for severe-range pressures (160/110) to intervene. Treating mild chronic
hypertension in pregnancy at 140/90 mmHg significantly reduces preeclampsia with
severe features and medically indicated preterm birth without compromising fetal growth.
Q5: A 68-year-old female with Heart Failure with Preserved Ejection Fraction (HFpEF) and
no history of diabetes is maximally titrated on an ARB and beta-blocker. What is the 2026
ACC/AHA Class 2a recommended addition to her regimen? A) A GLP-1 Receptor Agonist
, (e.g., Semaglutide) B) A Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (e.g., Dapagliflozin)
C) A direct renin inhibitor (e.g., Aliskiren) D) An Angiotensin-Converting Enzyme (ACE) inhibitor
● The Answer: B
● Distractor Analysis: Option A (GLP-1 RA) has metabolic benefits but no proven direct
efficacy in reducing HF hospitalizations in non-diabetic HFpEF patients. Option C is
contraindicated with an ARB. Option D is redundant and dangerous alongside an ARB.
● The Mentor's Analysis: SGLT2 inhibitors are the greatest pharmacological breakthrough
in heart failure of the decade. They promote osmotic diuresis, reduce preload, and alter
myocardial metabolism independently of insulin pathways. They are indicated for HFpEF
and HFrEF regardless of the patient's diabetes status.
Q6: A 52-year-old male with severe statin intolerance (myopathy) requires LDL-C
lowering. You prescribe Bempedoic acid. What is the precise mechanism of action, and
what specific adverse effect must you monitor? A) Inhibits NPC1L1 transporter; monitor for
cholelithiasis B) Inhibits HMG-CoA reductase; monitor for rhabdomyolysis C) Inhibits ATP-citrate
lyase (ACLY); monitor for hyperuricemia and gout D) Binds PCSK9 receptors; monitor for
injection site reactions
● The Answer: C
● Distractor Analysis: Option A describes Ezetimibe. Option B describes Statins. Option D
describes PCSK9 monoclonal antibodies (e.g., Evolocumab).
● The Mentor's Analysis: Bempedoic acid works upstream of HMG-CoA reductase by
inhibiting ATP-citrate lyase. Crucially, it is a prodrug activated only in the liver, not in
skeletal muscle, which completely bypasses statin-associated muscle symptoms (SAMS).
However, it competes with uric acid transporters in the kidney, increasing the risk of
hyperuricemia and gout flares.
Q7: According to the 2026 HRSA Women's Preventive Services Guidelines, what is the
mandate regarding breast cancer screening for average-risk women? A) Initiate biennial
screening at age 50; supplemental imaging requires a specialist co-pay. B) Initiate screening no
earlier than 40 and no later than 50; supplemental imaging for dense breasts must be covered
without cost-sharing. C) Initiate screening at age 35 for all women; annual MRI is required. D)
Discontinue all screening at age 65 regardless of health status.
● The Answer: B
● Distractor Analysis: Option A relies on outdated cost-sharing loopholes. Option C is too
aggressive and ignores risk stratification. Option D incorrectly applies cervical cancer exit
criteria to breast cancer, which continues to at least age 74.
● The Mentor's Analysis: HRSA closed a massive health equity gap in 2026. Plans must
provide first-dollar coverage (no cost-sharing) not just for the initial mammogram between
40-50, but for any required reflex imaging (ultrasound/MRI) and pathology needed to rule
out malignancy in dense breasts. This stops patients from abandoning diagnostic workups
due to surprise billing.
Q8: A 38-year-old female smoker (1 pack/day) with a BP of 145/92 mmHg requests
contraception. According to the U.S. Medical Eligibility Criteria (USMEC), which option is
a Category 4 (unacceptable health risk)? A) Copper IUD B) Levonorgestrel IUD C)
Progestin-only pill (POP) D) Combined Oral Contraceptive (COC) pill
● The Answer: D
● Distractor Analysis: Options A, B, and C do not contain estrogen and lack the profound
pro-thrombotic and vasoactive risks associated with synthetic estrogen metabolism in the
liver.
● The Mentor's Analysis: Synthetic estrogen increases hepatic production of clotting
